ALSO NOTED: Pfizer beefs up Chantix suicide warning; Actavis buys Italian Pfizer plant;

> Pfizer strengthened the suicide warning on its stop-smoking drug Chantix as the FDA reviews reports of patients who experienced psychiatric problems while on the drug. Report

> Generics maker Actavis has agreed to buy a Pfizer manufacturing facility that specializes in cancer treatments; the plant is near Milan, Italy, and employs about 340. Release

> The British Medical Association bristled at a government report suggesting that doctors overprescribe brand-name meds, while the pharma industry needled the NHS for being slow to adopt new drugs. Report

> India asked Indonesia to remove trade barriers that inhibit the importation of Indian drugs. Report

> India's Nicholas Piramal boosted its net profit by 31 percent in the third quarter as revenues rose to 7.36 billion rupees, or $188 million. Report

> Scientists in California made embryo clones of two men, a step toward developing new stem cells for therapeutic purposes. Report

> There's been a growing understanding in the drug development world that studies boasting of positive data on a drug tend to get published in the scientific literature with great fanfare; negative studies are often silently allowed to sink out from sight. Report

And Finally... The most aggressive form of skin cancer, Merkel cell carcinoma, may be caused by a previously unknown virus. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.